BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 13, 2025
Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
Immuno-oncology RSS Feed RSS

Immuno-oncology

ADCE-T02 ADC against tissue factor shows strong antitumor activity

May 8, 2025
No Comments
The expression of tissue factor (TF) is limited in normal tissues to the perivascular compartment where it acts as the receptor for the serin protease factor VIIa. This signaling axis triggers the initiation of extrinsic coagulation protease cascade.
Read More
Immuno-oncology

Preclinical results from a new HPV16/18 mRNA-based vaccine presented

May 8, 2025
No Comments
Metis Pharmaceuticals Inc. recently presented a novel mRNA-encoded human papillomavirus (HPV) 16/18 therapeutic vaccine for HPV-driven malignancies.
Read More
3D illustration of human digestive system
Immuno-oncology

LM-350 shows strong antitumor activity in CDH17-positive models

May 7, 2025
No Comments
Cadherin 17 (CDH17) is a membrane-bound cell adhesion molecule involved in tumor cell proliferation and is selectively overexpressed in several gastrointestinal malignancies, including colorectal cancer, gastric cancer and pancreatic cancer.
Read More
Immuno-oncology

Beigene’s BGB-A3055 inhibits tumor growth in cancer rodent models

May 7, 2025
No Comments
Beigene Co. Ltd. has presented data on their anti-CCR8 antibody BGB-A3055 as a cancer immunotherapeutic approach.
Read More
Antibody-drug conjugate
Immuno-oncology

Formosa and Almac Discovery sign license agreement for EGFRxROR1 bispecific ADC

May 7, 2025
No Comments
Formosa Pharmaceuticals Inc. and Almac Discovery Ltd. have announced a global licensing agreement for development and commercialization of ALM-401, a first-in-class engineered bispecific antibody-drug conjugate (ADC) for the treatment of solid tumors characterized by the dual expression of EGFR and ROR1.
Read More
Head and neck anatomy

Immutep’s efti shows strong survival data in head and neck cancer

May 6, 2025
By Tamra Sami
No Comments
Immutep Ltd. announced strong median overall survival of 17.6 months in cohort B of the TACTI-003 (Keynote-PNC-34) phase IIb trial that evaluated eftilagimod alfa in combination with Merck & Co.’s Keytruda (pembrolizumab) as first-line therapy in recurrent/metastatic head and neck squamous cell carcinoma in patients with PD-L1 expression below 1.
Read More
Hand pointing to IPOs on line graph

Three Korea biotechs prep for May IPOs

May 6, 2025
By Marian (YoonJee) Chu
Among three Korean biotech companies slated to sell shares on the Korea Exchange this month, Immuneoncia Therapeutics Inc. is the latest to price a ₩33.9 billion (US$24 million) Kosdaq IPO for May 19. Regenerative cell therapy maker Organoid Sciences Ltd. and antibody-drug conjugate specialist Intocell Inc. are also gearing up for respective Kosdaq listings starting next week.
Read More
Immuno-oncology

Xenothera details preclinical characterization of XON-9

May 6, 2025
No Comments
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-associated deaths worldwide.
Read More
Head and neck anatomy

Immutep’s efti shows strong survival data in head and neck cancer

May 5, 2025
By Tamra Sami
No Comments
Immutep Ltd. announced strong median overall survival of 17.6 months in cohort B of the TACTI-003 (Keynote-PNC-34) phase IIb trial that evaluated eftilagimod alfa in combination with Merck & Co.’s Keytruda (pembrolizumab) as first-line therapy in recurrent/metastatic head and neck squamous cell carcinoma in patients with PD-L1 expression below 1.
Read More
Illustration of human papillomavirus particles
Immuno-oncology

Ad-E6/7-HR shows prophylactic and therapeutic preclinical efficacy in HPV-associated cancers

May 5, 2025
No Comments
Human papillomavirus (HPV), particularly the high-risk HPV16 subtype, is a major driver of certain cancers, including cervical, oropharyngeal, anal and penile cancers. The E6 and E7 proteins produced by HPV16 are known to play critical roles in the development of these malignancies, making them attractive targets for therapeutic interventions.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 967 968 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 12, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Stock merger illustration

    Biontech’s $1.25B Curevac buyout removes mRNA lawsuit uncertainty

    BioWorld
    Three years after litigation started over technology used in an mRNA vaccine for COVID-19, Biontech SE is acquiring its adversary, Curevac NV, through an...
  • Multiple myeloma illustration

    Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset

    BioWorld
    Cullinan Therapeutics Inc. swept up ex-China rights to a multiple myeloma-targeting BCMAxCD3 bispecific T-cell engager (BiTE) velinotamig from Chongqing Genrix...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing